Updates and news related to prostate cancer:
Steven Rowe, MD, PhD, provides some of the background on the PSMA-PET imaging revolution in prostate cancer and offered his insight.
The findings could enable doctors to detect early on, without invasive procedures, if a treatment is working and switch to alternatives such as abiraterone or cabazitaxel if it is not.
The proteins were only predictive for African-American patients, not European-American patients.
Omission of transitional-zone sampling during the systematic portion of combined biopsy reliably detected clinically significant prostate cancer.
Prostate MRI and genomic testing may improve the precision of management and support observation of prostate cancer.
Dr. Alicia Morgans discusses biomarker testing protocols and signs to look for during testing.
An update to active surveillance recommendations has some physicians concerned.
Findings suggest dietary interventions may help reduce risk and were published in Cancer Epidemiology, Biomarkers & Prevention.
Total Androgen Suppression Does Not Improve Overall Survival for Certain Patients With Prostate Cancer
Study does not show clinically significant improvements in overall survival but does show benefits in secondary endpoints, which included rates of distant metastases, deaths due to prostate cancer, and PSA failure.
Abiraterone plus prednisolone added to ADT significantly decreases the risk for metastasis and death compared with ADT alone in patients with high-risk nonmetastatic prostate cancer, new findings suggest.